Retatrutide FDA Approval: Status, Timeline and Sourcing Rules

No. As of October 10, 2026, retatrutide has no FDA approval for any use, and no approved dose exists. It is an investigational drug, meaning it is permitted only in studies and special access programs.

On July 23, 2026, Lilly announced that it plans to submit its U.S. marketing application in the first quarter of 2027, in its investor release on the phase 3 obesity trials. A plan to file is not a filing, and a filing is not an approval. FDA decides after reviewing the evidence for specific uses, and it can approve, request more data, or decline.

On our model, a decision lands between September 2027 and March 2028 if Lilly files in Q1 2027. FDA's published review goals for a new molecular entity (a drug whose active ingredient has never been approved) are 10 months for a standard review and 6 months for a priority review. Both are counted from the 60-day filing date, so the total from submission is 12 months or 8 months. The source is FDA's PDUFA reauthorization performance goals, which state that the review clock begins at the end of the 60-day filing review period. PDUFA is the Prescription Drug User Fee Act. FDA notifies the applicant within 60 days of receipt whether priority review applies, per FDA's priority review page.

The totals are our arithmetic: 60 days is about 2 months, so 6 + 2 = 8 months and 10 + 2 = 12 months. The model assumes retatrutide is reviewed as a new molecular entity and that FDA meets its goal without extending it. It is a model, not an FDA forecast.

If Lilly files later than Q1 2027, the window moves by the same amount. Our recommendation: plan on the standard track and on 2028 for any prescribing or supply plan, and treat anything earlier as a bonus. Approval also does not mean instant availability, since a launch follows the decision.

Yes, through two routes only: enrolling in a clinical trial, or an expanded access request submitted by the treating physician. Expanded access is the FDA pathway that lets a patient with a serious condition receive an unapproved drug outside a trial when no trial or approved treatment fits.

Lilly sponsors a program listed on ClinicalTrials.gov as Pre-approval Expanded Access of Retatrutide (NCT07629401). The patient must meet all of these criteria:

• The patient is an adult with severe obesity (BMI of 35 kg/m² or higher) despite maximum-dose chronic weight management therapy.
• The patient has at least two serious or life-threatening obesity-related complications for which they are currently receiving standard of care.
• The patient cannot access an ongoing retatrutide clinical trial.
• Standard treatment options, including bariatric surgery, have been discussed with the patient.

A medical contraindication to retatrutide excludes a patient. Patients cannot apply directly. Treating physicians contact Lilly through the Lilly Answers Center at 1-800-LillyRx (1-800-545-5979), as the record states.

The practical order is to search ClinicalTrials.gov for retatrutide for a recruiting trial first, and to ask your physician about expanded access only if none fits. A BMI below 35 kg/m² does not meet the program's criteria. Most people will not qualify, and that is by design.

Because FDA judges a product by how it is marketed and what it is intended for, not by the disclaimer on the label. FDA states that retatrutide is not a component of any FDA-approved drug and has not been found safe and effective for any condition. FDA also notes that companies have sold unapproved drugs labeled "for research purposes" or "not for human consumption" directly to consumers with dosing instructions (FDA, October 1, 2026).

A March 31, 2026 FDA warning letter to Gram Peptides shows how this works. The seller labeled retatrutide and tirzepatide "not intended for human consumption". Its website, however, described appetite suppression and insulin effects and offered bacteriostatic water for injection alongside the vials. FDA concluded the products were intended as drugs, cited sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act, and warned that injectable products pose "risks of serious harm" by bypassing the body's defenses.

The common objection is "it's the same molecule, so what's the difference?" The difference is review. FDA's position is that unapproved versions "do not undergo FDA's review for safety, effectiveness and quality before they are marketed." FDA lists improper storage, fraudulent labeling and dosing errors among the risks of unapproved GLP-1 products, and it reports adverse events, some requiring hospitalization, that may be related to dosing errors.

Patients and clinicians should use a clinical trial or Lilly's expanded access program. Telehealth operators and compounders should not market, compound or dispense retatrutide. Importers should confirm end use, destination authority and FDA's written position before any request for quotation.

The alert does not name retatrutide, so you need FDA's written position before assuming either way. Import Alert 66-80, dated October 9, 2026, covers detention without physical examination of GLP-1 receptor agonist bulk drug substances and names semaglutide, tirzepatide, liraglutide, exenatide, dulaglutide, lixisenatide, orforglipron and two insulins. It also lists catch-all product codes for unlisted anti-diabetic and hormone products.

The alert states that FDA made onsite inspections and remote regulatory assessments of 48 GLP-1 API (active pharmaceutical ingredient) sites and found 21%, roughly 10 sites, noncompliant under section 501 of the Federal Food, Drug, and Cosmetic Act. Its Green List names the firms and drugs that met the criteria for exclusion from detention.

Our inference: because the Green List is built from firms with products that meet FDA's standards, a molecule with no approved product has no clear route onto it. That is why the right test is a written answer from FDA, not an assumption in either direction. For a U.S. destination, a lawful end use for an unapproved API is narrow. In our view, the realistic examples are supply to a sponsor operating under an FDA-cleared investigational new drug application, or a non-U.S. destination where the buyer's own authority permits the import and use.

For the wider qualification steps that apply to any imported API, see our qualification map for API suppliers serving US importers. For a GLP-1 molecule that does have approved finished products, our guide to what a US buyer must verify first for tirzepatide API shows the contrast.

We supply retatrutide as bulk API (raw powder) to qualified B2B buyers, not as finished vials and not for consumer sale. We publish this page and supply this material, which you should weigh when reading our sourcing advice. We do not represent retatrutide as an approved human pharmaceutical API, and we make no claim of U.S. registration for it. Regulatory status and permitted end use are decided product by product and destination by destination. The buyer confirms local registration, import authorization and permitted end use before commercial supply. Our retatrutide API page lists the product, and our checklist for peptide API supply chain qualification sets out how we expect a buyer to qualify any peptide source.

Sample and evaluation quantities are supported for qualified buyers, with a certificate of analysis (COA), specification and safety data sheet (SDS) where applicable. Pricing is confirmed per product at quotation, so ask us for a quote through our contact page.

Run these five tests with every supplier, including us, before you pay: